Source 1review2024MED
Toolkit/NGF-overexpressing mesenchymal stem cells
NGF-overexpressing mesenchymal stem cells
Also known as: MSCs genetically modified to overexpress NGF
Taxonomy: Mechanism Branch / Architecture. Workflows sit above the mechanism and technique branches rather than replacing them.
Summary
Additionally, mesenchymal stem cells (MSCs) genetically modified to overexpress NGF could provide trophic support.
Usefulness & Problems
Why this is useful
This proposed construct uses MSCs engineered to overexpress NGF. The intended function is to provide trophic support in the setting of impaired NGF-TrkA signaling.; providing trophic support in CIPA; cell-based delivery of NGF-related support
Source:
This proposed construct uses MSCs engineered to overexpress NGF. The intended function is to provide trophic support in the setting of impaired NGF-TrkA signaling.
Source:
providing trophic support in CIPA
Source:
cell-based delivery of NGF-related support
Problem solved
It is meant to support cells affected by deficient NGF signaling in CIPA.; aims to compensate for deficient NGF signaling support in CIPA
Source:
It is meant to support cells affected by deficient NGF signaling in CIPA.
Source:
aims to compensate for deficient NGF signaling support in CIPA
Problem links
aims to compensate for deficient NGF signaling support in CIPA
LiteratureIt is meant to support cells affected by deficient NGF signaling in CIPA.
Source:
It is meant to support cells affected by deficient NGF signaling in CIPA.
Taxonomy & Function
Primary hierarchy
Mechanism Branch
Architecture: A reusable architecture pattern for arranging parts into an engineered system.
Techniques
No technique tags yet.
Target processes
editingImplementation Constraints
cofactor dependency: cofactor requirement unknownencoding mode: genetically encodedimplementation constraint: context specific validationoperating role: regulator
It requires mesenchymal stem cells and genetic modification to drive NGF overexpression. The abstract does not specify vector system, manufacturing, or delivery route.; requires mesenchymal stem cells engineered to overexpress NGF
The abstract does not show that NGF-overexpressing MSCs restore normal function in CIPA patients, and it does not establish cure-level efficacy.; presented as a proposed strategy rather than established therapy
Validation
Cell-freeBacteriaMammalianMouseHumanTherapeuticIndep. Replication
Supporting Sources
Ranked Claims
The review proposes stem-cell-based and modern genetic strategies including iPSC neuronal replacement, in vivo gene editing, NGF-overexpressing MSCs, epigenetic modulation of NTRK1, and exosome-mediated gene therapy as hypothesis-level approaches for CIPA.
Approval Evidence
1 source1 linked approval claimfirst-pass slug ngf-overexpressing-mesenchymal-stem-cells
Additionally, mesenchymal stem cells (MSCs) genetically modified to overexpress NGF could provide trophic support.
Source:
therapeutic hypothesissupports
The review proposes stem-cell-based and modern genetic strategies including iPSC neuronal replacement, in vivo gene editing, NGF-overexpressing MSCs, epigenetic modulation of NTRK1, and exosome-mediated gene therapy as hypothesis-level approaches for CIPA.
Source:
Comparisons
Source-stated alternatives
The review also proposes iPSC replacement, in vivo gene editing of neural progenitors, epigenetic modulation of NTRK1 expression, and exosome-mediated gene therapy.
Source:
The review also proposes iPSC replacement, in vivo gene editing of neural progenitors, epigenetic modulation of NTRK1 expression, and exosome-mediated gene therapy.
Source-backed strengths
explicitly proposed to provide trophic support
Source:
explicitly proposed to provide trophic support
Compared with Exosomes
The review also proposes iPSC replacement, in vivo gene editing of neural progenitors, epigenetic modulation of NTRK1 expression, and exosome-mediated gene therapy.
Shared frame: source-stated alternative in extracted literature
Strengths here: explicitly proposed to provide trophic support.
Relative tradeoffs: presented as a proposed strategy rather than established therapy.
Source:
The review also proposes iPSC replacement, in vivo gene editing of neural progenitors, epigenetic modulation of NTRK1 expression, and exosome-mediated gene therapy.
Compared with gene therapy
The review also proposes iPSC replacement, in vivo gene editing of neural progenitors, epigenetic modulation of NTRK1 expression, and exosome-mediated gene therapy.
Shared frame: source-stated alternative in extracted literature
Strengths here: explicitly proposed to provide trophic support.
Relative tradeoffs: presented as a proposed strategy rather than established therapy.
Source:
The review also proposes iPSC replacement, in vivo gene editing of neural progenitors, epigenetic modulation of NTRK1 expression, and exosome-mediated gene therapy.
Ranked Citations
- 1.